We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New High Throughput NMR Spectroscopy Platform For INRS
News

New High Throughput NMR Spectroscopy Platform For INRS

New High Throughput NMR Spectroscopy Platform For INRS
News

New High Throughput NMR Spectroscopy Platform For INRS

INRS, Canada
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New High Throughput NMR Spectroscopy Platform For INRS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Implementation of a new nuclear magnetic resonance (NMR) spectroscopy platform will provide professors Nicolas Doucet and Steven LaPlante of Centre INRS–Institut Armand-Frappier with a powerful new tool for conducting an ambitious research program aimed at identifying new therapeutic molecules. This new platform, funded in part by the Canadian Foundation for Innovation’s John R. Evans Leaders Fund and the Government of Quebec, will enable the two researchers to explore the role of atomic-scale molecular motions in protein and enzyme families involved in amyotrophic lateral sclerosis (ALS), diabetes, asthma, HIV, auto-immune disease, and cancer.

Pooling their parallel expertise in protein NMR and drug discovery, professors Doucet and LaPlante will have access to a 600 megahertz NMR spectrometer with high throughput screening capabilities to characterize biomolecular interactions between proteins and their ligands. The knowledge gained will be crucial to fragment-based drug discovery (FBDD), a new pharmaceutical approach aimed at developing targeted and more effective drugs that cause fewer side effects.

This new research capability has the potential to revolutionize drug development practices and to provide new impetus to the pharmaceutical industry in Quebec and across Canada. It will also offer a unique training environment for highly skilled biotechnology personnel.

This article has been republished from materials provided by INRS. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement